Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 First-in-Human Study of REGN5458 in Relapsed or Refractory Multiple Myeloma (Japan cohort)
jRCT2031230087Phase 2Active, not recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jan 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label, single-arm trial of linvoseltamab in multiple myeloma (MM), sponsored by Regeneron Pharmaceuticals. Started Jan 2024; status: active, not recruiting.
02
Drugs
linvoseltamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2031230087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230087.